How deleting one sneaky protein helps liver cancer immunotherapy in mice

A sneaky chemical bribe

Why does liver cancer shrug off the body's natural defences? In hepatocellular carcinoma, the most common primary liver cancer, tumours build a hostile microenvironment that silences patrolling immune cells. Standard liver cancer immunotherapy frequently fails because this barrier tells the body to stand down.

Searching through thousands of genes

To find the culprit, researchers ran a CRISPR-knockout screen in mice, switching off 4,500 candidate genes one by one. A single gene encoding ribosomal protein S19, or RPS19, stood out. When active, tumour cells produce this protein to send a hush signal directly to nearby defence cells known as tumour-associated macrophages.

Using human tissue samples and mouse assays, the team tracked this message to a specific docking bay on the macrophages called the C5aR1 receptor. RPS19 effectively acts like a corrupt official bribing security guards to look the other way. Once bribed, these macrophages switch from attacking the tumour to protecting it.

Nanoparticles with a secret lock

Knowing the target was not enough; the researchers needed a way to strike it directly inside tumours. They built specialised delivery capsules called SNPSS nanoparticles. These tiny couriers carried CRISPR gene-editing machinery and navigated straight to liver cancer cells using a targeting peptide.

Inside the chemical-rich tumour space, the nanoparticles dissolved and released their cargo. Cutting out RPS19 cut off the bribe to the macrophages, revived local immune defences, and halted tumour growth in living mice.

What we still don't know

These findings show clear therapeutic potential, but strictly in preclinical mouse models and human tissue samples rather than living patients. Mice do not fully mirror human biology, and researchers only tested 4,500 genes rather than the entire genome. We still do not know if SNPSS nanoparticles are entirely safe for humans, or how well targeting RPS19 will work alongside existing immunotherapies in clinical trials.